Evidence map›Paper›PMID 39503511›Full record

ArticleClinical science (London, England : 1979)2024

Endothelin-1 receptor blockade impairs invasion patterns in engineered 3D high-grade serous ovarian cancer tumouroids.

Judith Pape, Umber Cheema, Piera Tocci, Rosanna Sestito, Ilenia Masi, Marilena Loizidou, Anna Bagnato, Laura Rosanò

Abstract read
In one paragraph

Article in Clinical science (London, England : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Judith PapeUCL Division of Surgery and Interventional Science, London, U.K.
Umber CheemaUCL Division of Surgery and Interventional Science, London, U.K.
Piera TocciUnit of Preclinical Models and New Therapeutic Agents, IRCCS, Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0003-3771-013X
Rosanna SestitoUnit of Preclinical Models and New Therapeutic Agents, IRCCS, Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0001-5460-2777
Ilenia MasiInstitute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), Rome, 00185, Italy.
Marilena LoizidouUCL Division of Surgery and Interventional Science, London, U.K.
Anna BagnatoUnit of Preclinical Models and New Therapeutic Agents, IRCCS, Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0002-7269-9522
Laura RosanòUnit of Preclinical Models and New Therapeutic Agents, IRCCS, Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0002-9962-6411

Funding

Associazione Italiana Ricerca sul Cancro 21327Associazione Italiana Ricerca sul Cancro IG22835Ministero della Salute (Italy Ministry of Health) RF-2019-12368718PRIN 2022 PNRR - European Union -Next Generation EU P2022Z7TEC
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HG-SOC), accounting for 70-80% of ovarian cancer deaths, is characterized by a widespread and rapid metastatic nature, influenced by diverse cell types, cell-cell interactions, and acellular components of the tumour microenvironment (TME). Within this tumour type, autocrine and paracrine activation of the endothelin-1 receptors (ET-1R), expressed in tumour cells and stromal elements, drives metastatic progression. The lack of three-dimensional models that faithfully recapitulate the unique HG-SOC TME has been the bottleneck in performing drug screening for personalized medicine. Herein, we developed HG-SOC tumouroids by engineering a dense central artificial cancer mass (ACM) containing HG-SOC cells, nested within a compressed hydrogel recapitulating the stromal compartment comprising type I collagen, laminin, fibronectin, and stromal cells (fibroblasts and endothelial cells). ET-1-stimulated HG-SOC cells in the tumouroids showed an altered migration pattern and formed cellular aggregates, mimicking micrometastases that invaded the stroma. Compared with control cells, ET-1-stimulated tumouroids showed a higher number of invasive bodies, which were reduced by treatment with the dual ET-1 receptor (ET-1R) antagonist macitentan. In addition, ET-1 increased the size of the invading aggregates compared with control cells. This study establishes an experimental 3D multicellular model eligible for mechanical research, investigating the impact of matrix stiffness and TME interactions, which will aid drug screening to guide therapeutic decisions in HG-SOC patients.

Indexed as

Neoplasm InvasivenessOvarian NeoplasmsReceptor, Endothelin ATumor MicroenvironmentCell Line, TumorCell MovementCystadenocarcinoma, SerousEndothelin-1Endothelin A Receptor AntagonistsFemaleHumansNeoplasm GradingPyrimidinesSulfonamidesEndothelin-1Endothelin A Receptor AntagonistsmacitentanPyrimidinesReceptor, Endothelin ASulfonamidesendothelinsovarian cancerstromatumoroid

Identifiers

PMID39503511
PMCPMC11570180

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.